A phase II study to evaluate the gastrointestinal safety of ATB-346 versus naproxen

Trial Profile

A phase II study to evaluate the gastrointestinal safety of ATB-346 versus naproxen

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs ATB 346 (Primary) ; Naproxen
  • Indications Pain
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 02 Aug 2017 According to an Antibe Therapeutics media release, this study will be completed in early 2018.
    • 02 Aug 2017 According to an Antibe Therapeutics media release, the company has received approval from Health Canada to initiate this study. Antibe therapeutics expects to initiate the study immediately and will be performed by Topstone Research, in Toronto.
    • 18 Apr 2017 According to an Antibe Therapeutics media release, this trial is expected to begin in 3Q 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top